Hank, I completely agree with you. If I were thinking of starting a biotech company, the US markets would not be my first choice. The once small cottage industry of ripping off investors of small fledgling companies, has now become a commonplace profit center for hedgefunds and market makers not smart enough to do business legitimately.
Honestly, I can't imagine seeking a profit by shorting and spoofing a company that is bringing a badly needed cancer treatment platform to market, I really can't.
Hopefully, more than a few people end up in jail.
Regards.